Quality evaluation of esophageal cancer clinical guidelines and consensus_Chinese Journal of Evidence-Based Medicine

Authors：

SHAO Lihua ¹ , ZHANG Qiuning ^2,3 , TIAN Jinhui ⁴ , YANG Zhen ⁴ , LUO Hongtao ^1,5 , LIU Ruifeng ^1,5 , LIAO Yiran ¹ , GENG Yichao ¹ ,  WANG Xiaohu ^1,3,4,5 , YANG Kehu ⁴

1. Department of Radiation Oncology, The First Clinical Medical College of Lanzhou University, Lanzhou 730000, P.R.China;
2. Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, P.R.China;
3. Lanzhou Heavy Ion Hospital, Lanzhou 730000, P.R.China;
4. Basic Medical College of Lanzhou University, Lanzhou 730000, P.R.China;
5. Department of Radiation Oncology, Gansu Provincial Cancer Hospital, Lanzhou 730050, P.R.China;

Corresponding?author：

WANG Xiaohu, Email: xhwanggansu@163.com

Keywords：

Clinical guideline; Consensus; Quality assessment; AGREE Ⅱ; RIGHT

DOI：

10.7507/1672-2531.201909072

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To evaluate the methodological and reporting quality of clinical guidelines and consensus for esophageal cancer.Methods Databases including PubMed, EMbase, Web of Science, CBM, WanFang Data and CNKI were electronically searched and major guideline websites such as GIN, NICE, NGC and Yimaitong were also searched to collect guidelines and consensus for esophageal cancer from inception to August 2018. Two reviewers independently screened the literatures and extracted data according to the inclusion and exclusion criteria and then evaluated the quality of the included guidelines using the AGREE II and RIGHT instruments.Results A total of 26 esophageal cancer guidelines and consensus were included. The mean scores for each domain of AGREE II was 49.63% for scope and purpose, 25.16% for stakeholder involvement, 23.42% for rigor of development, 49.25% for clarity of presentation, 16.91% for applicability, and 21.07% for editorial independence. The item with the highest reporting rate among the RIGHT evaluation items was 5 (84.62%), followed by 1a (80.77%), 1c (65.38%), 13a (65.38%), and 4 (61.54%), and the remaining items were all reported below 50%. Results of subgroup analysis showed that the guidelines and consensus developed based on the evidence-based medicine method had higher average scores in the six domains of AGREE II and the RIGHT score than the guidelines and consensus developed based on expert opinions or reviews. The foreign guidelines and consensus had higher average scores in the three domains of AGREE II (formulation rigor, clarity, editorial independence) and the RIGHT score than the domestic guidelines.Conclusions The methodological and reporting quality of the guidelines and consensus on esophageal cancer is low, with the guidelines and consensus in China even lower, requiring further improvement. It is suggested that the guideline developers should refer to the standards such as AGREE II and RIGHT to develop high-quality guidelines and promote their application, so as to better guide the standardized diagnosis and treatment of esophageal cancer.

Citation： SHAO Lihua, ZHANG Qiuning, TIAN Jinhui, YANG Zhen, LUO Hongtao, LIU Ruifeng, LIAO Yiran, GENG Yichao, WANG Xiaohu, YANG Kehu. Quality evaluation of esophageal cancer clinical guidelines and consensus. Chinese Journal of Evidence-Based Medicine, 2020, 20(5): 593-603. doi: 10.7507/1672-2531.201909072 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	Institute of Medicine (US). Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Clinical practice guidelines we can trust. Washington: National Academies Press, 2011.
3.	Qaseem A, Forland F, Macbeth F, et al. Guidelines International Network: toward international standards for clinical practice guidelines. Ann Intern Med, 2012, 156(7): 525-531.
4.	Moher D, Schulz KF, Simera I, et al. Guidance for developers of health research reporting guidelines. PLoS Med, 2010, 7(2): e1000217.
5.	AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care, 2003, 12(1): 18-23.
6.	Brouwers MC, Kho ME, Browman GP, et al. AGREE Ⅱ: advancing guideline development, reporting, and evaluation in health care. Prev Med, 2010, 51(5): 421-424.
7.	Chen Y, Yang K, Maru?i? A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Z Evid Fortbild Qual Gesundhwes, 2017, 127-128: 3-10.
8.	Cancer Control Alberta. Management of patients with early esophageal cancer, dysplastic and non-dysplastic Barrett's esophagus. 2014. Available from: https://www.guidelinecentral.com/summaries/management-of-patients-with-early-esophageal-cancer-dysplastic-and-non-dysplastic-barretts-esophagus/.
9.	Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers (Version 2.2019), NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2019, 17(7): 855-883.
10.	Evans JA, Early DS, et al. ASGE Standards of Practice Committee. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc, 2013, 77(3): 328-334.
11.	Varghese TK Jr, Hofstetter WL, Rizk NP, et al. The Society of Thoracic Surgeons guidelines on the diagnosis and staging of patients with esophageal cancer. Ann Thorac Surg, 2013, 96(1): 346-356.
12.	Gaspar LE, Nag S, Herskovic A, et al. Clinical Research Committee, American Brachytherapy Society, American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Int J Radiat Oncol Biol Phys, 1997, 38(1): 127-132.
13.	毛友生, 楊丁, 高樹庚, 等. 胸段食管癌手術入路選擇爭議與共識. 中華胃腸外科雜志, 2016, 19(9): 961-964.
14.	Whiteman DC, Appleyard M, Bahin FF, et al. Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol, 2015, 30(5): 804-820.
15.	Palmes D, Br wer M, Bader FG, et al. Diagnostic evaluation, surgical technique, and perioperative management after esophagectomy: consensus statement of the German Advanced Surgical Treatment Study Group. Langenbecks Arch Surg, 2011, 396(6): 857-866.
16.	Stahl M, Oliveira J. Esophageal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009, 20(Suppl 4): 32-33.
17.	Wong R, Walker-Dilks C, Raifu A. Evidence-based guideline recommendations on the use of positron emission tomography imaging in oesophageal cancer. Clin Oncol (R Coll Radiol), 2012, 24(2): 86-104.
18.	Kuwano H, Nishimura Y, Oyama T, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus, 2015, 12(1): 1-30.
19.	Allum WH, Blazeby JM, Griffin SM, et al. Guidelines for the management of oesophageal and gastric cancer. Gut, 2011, 60(11): 1449-1472.
20.	Malthaner RA, Wong RK, Rumble RB, et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline. BMC Cancer, 2004, 4: 67.
21.	Jo Y. New consensus on the management of barrett's dysplasia and early stage esophageal adenocarcinoma: limited evidence, but best available guidance. J Neurogastroenterol Motil, 2012, 18(4): 455-456.
22.	Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2016, 27(suppl 5): v50-v57.
23.	Malthaner R, Wong RK, Spithoff K, et al. Preoperative or postoperative therapy for resectable oesophageal cancer: an updated practice guideline. Clin Oncol (R Coll Radiol), 2010, 22(4): 250-256.
24.	Martin-Richard M, DSaz Beveridge R, Arrazubi V, et al. SEOM clinical guideline for the diagnosis and treatment of esophageal cancer (2016). Clin Transl Oncol, 2016, 18(12): 1179-1186.
25.	Gallego J, Cervantes A, Pericay C, et al. SEOM clinical guidelines for the treatment of oesophageal cancer. Clin Transl Oncol, 2011, 13(8): 520-524.
26.	王雅棣, 路娜. 食管癌三維適形/調強放療劑量與范圍的共識與爭議. 世界華人消化雜志, 2016, 24(34): 4531-4536.
27.	中國醫師協會胸外科分會快速康復專家委員會. 食管癌加速康復外科技術應用專家共識(2016版). 中華胸心血管外科雜志, 2016, 32(12): 717-722.
28.	呂家華, 李濤, 謝叢華, 等. 食管癌放療患者腸內營養專家共識. 腫瘤代謝與營養電子雜志, 2015, 2(4): 29-32.
29.	李蘇宜. 食管癌和賁門癌腫瘤內科診治指南. 江蘇省抗癌協會化療專業委員會第五屆年會暨肺癌專題研討會論文集, 南京: 2004, 66-76.
30.	Allum WH, Blazeby JM, Griffin SM, et al. Association of upper gastrointestinal surgeons of Great Britain and Ireland, the British Society of Gastroenterology and the British Association of Surgical Oncology. Guidelines for the management of oesophageal and gastric cancer. Gut, 2011, 60(11): 1449-1472.
31.	于振濤. 食管胃交界腺癌手術治療共識與爭議. 中華胸部外科電子雜志, 2015, 2(1): 3-7.
32.	中華醫學會消化內鏡學分會中國抗癌協會腫瘤內鏡專業委員會. 中國早期食管癌篩查及內鏡診治專家共識意見精簡版(2014年, 北京). 中華消化雜志, 2015, 35(5): 294-299.
33.	中華醫學會消化內鏡學分會消化系早癌內鏡診斷與治療協作組, 中華醫學會消化病學分會消化道腫瘤協作組, 中華醫學會消化病學分會消化病理學組. 中國早期食管鱗狀細胞癌及癌前病變篩查與診治共識(2015年, 北京). 中華消化內鏡雜志, 2016, (1): 3-18.
34.	World Health Organization. Guidelines for WHO guidelines. 2003. Available from: https://apps.who.int/iris/bitstr eam/handle/ 10665/68925/EIP_GPE_EQC_2003_1.pdf;sequence=1.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. Institute of Medicine (US). Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Clinical practice guidelines we can trust. Washington: National Academies Press, 2011.
3. Qaseem A, Forland F, Macbeth F, et al. Guidelines International Network: toward international standards for clinical practice guidelines. Ann Intern Med, 2012, 156(7): 525-531.
4. Moher D, Schulz KF, Simera I, et al. Guidance for developers of health research reporting guidelines. PLoS Med, 2010, 7(2): e1000217.
5. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care, 2003, 12(1): 18-23.
6. Brouwers MC, Kho ME, Browman GP, et al. AGREE Ⅱ: advancing guideline development, reporting, and evaluation in health care. Prev Med, 2010, 51(5): 421-424.
7. Chen Y, Yang K, Maru?i? A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Z Evid Fortbild Qual Gesundhwes, 2017, 127-128: 3-10.
8. Cancer Control Alberta. Management of patients with early esophageal cancer, dysplastic and non-dysplastic Barrett's esophagus. 2014. Available from: https://www.guidelinecentral.com/summaries/management-of-patients-with-early-esophageal-cancer-dysplastic-and-non-dysplastic-barretts-esophagus/.
9. Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers (Version 2.2019), NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2019, 17(7): 855-883.
10. Evans JA, Early DS, et al. ASGE Standards of Practice Committee. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc, 2013, 77(3): 328-334.
11. Varghese TK Jr, Hofstetter WL, Rizk NP, et al. The Society of Thoracic Surgeons guidelines on the diagnosis and staging of patients with esophageal cancer. Ann Thorac Surg, 2013, 96(1): 346-356.
12. Gaspar LE, Nag S, Herskovic A, et al. Clinical Research Committee, American Brachytherapy Society, American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Int J Radiat Oncol Biol Phys, 1997, 38(1): 127-132.
13. 毛友生, 楊丁, 高樹庚, 等. 胸段食管癌手術入路選擇爭議與共識. 中華胃腸外科雜志, 2016, 19(9): 961-964.
14. Whiteman DC, Appleyard M, Bahin FF, et al. Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol, 2015, 30(5): 804-820.
15. Palmes D, Br wer M, Bader FG, et al. Diagnostic evaluation, surgical technique, and perioperative management after esophagectomy: consensus statement of the German Advanced Surgical Treatment Study Group. Langenbecks Arch Surg, 2011, 396(6): 857-866.
16. Stahl M, Oliveira J. Esophageal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009, 20(Suppl 4): 32-33.
17. Wong R, Walker-Dilks C, Raifu A. Evidence-based guideline recommendations on the use of positron emission tomography imaging in oesophageal cancer. Clin Oncol (R Coll Radiol), 2012, 24(2): 86-104.
18. Kuwano H, Nishimura Y, Oyama T, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus, 2015, 12(1): 1-30.
19. Allum WH, Blazeby JM, Griffin SM, et al. Guidelines for the management of oesophageal and gastric cancer. Gut, 2011, 60(11): 1449-1472.
20. Malthaner RA, Wong RK, Rumble RB, et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline. BMC Cancer, 2004, 4: 67.
21. Jo Y. New consensus on the management of barrett's dysplasia and early stage esophageal adenocarcinoma: limited evidence, but best available guidance. J Neurogastroenterol Motil, 2012, 18(4): 455-456.
22. Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2016, 27(suppl 5): v50-v57.
23. Malthaner R, Wong RK, Spithoff K, et al. Preoperative or postoperative therapy for resectable oesophageal cancer: an updated practice guideline. Clin Oncol (R Coll Radiol), 2010, 22(4): 250-256.
24. Martin-Richard M, DSaz Beveridge R, Arrazubi V, et al. SEOM clinical guideline for the diagnosis and treatment of esophageal cancer (2016). Clin Transl Oncol, 2016, 18(12): 1179-1186.
25. Gallego J, Cervantes A, Pericay C, et al. SEOM clinical guidelines for the treatment of oesophageal cancer. Clin Transl Oncol, 2011, 13(8): 520-524.
26. 王雅棣, 路娜. 食管癌三維適形/調強放療劑量與范圍的共識與爭議. 世界華人消化雜志, 2016, 24(34): 4531-4536.
27. 中國醫師協會胸外科分會快速康復專家委員會. 食管癌加速康復外科技術應用專家共識(2016版). 中華胸心血管外科雜志, 2016, 32(12): 717-722.
28. 呂家華, 李濤, 謝叢華, 等. 食管癌放療患者腸內營養專家共識. 腫瘤代謝與營養電子雜志, 2015, 2(4): 29-32.
29. 李蘇宜. 食管癌和賁門癌腫瘤內科診治指南. 江蘇省抗癌協會化療專業委員會第五屆年會暨肺癌專題研討會論文集, 南京: 2004, 66-76.
30. Allum WH, Blazeby JM, Griffin SM, et al. Association of upper gastrointestinal surgeons of Great Britain and Ireland, the British Society of Gastroenterology and the British Association of Surgical Oncology. Guidelines for the management of oesophageal and gastric cancer. Gut, 2011, 60(11): 1449-1472.
31. 于振濤. 食管胃交界腺癌手術治療共識與爭議. 中華胸部外科電子雜志, 2015, 2(1): 3-7.
32. 中華醫學會消化內鏡學分會中國抗癌協會腫瘤內鏡專業委員會. 中國早期食管癌篩查及內鏡診治專家共識意見精簡版(2014年, 北京). 中華消化雜志, 2015, 35(5): 294-299.
33. 中華醫學會消化內鏡學分會消化系早癌內鏡診斷與治療協作組, 中華醫學會消化病學分會消化道腫瘤協作組, 中華醫學會消化病學分會消化病理學組. 中國早期食管鱗狀細胞癌及癌前病變篩查與診治共識(2015年, 北京). 中華消化內鏡雜志, 2016, (1): 3-18.
34. World Health Organization. Guidelines for WHO guidelines. 2003. Available from: https://apps.who.int/iris/bitstr eam/handle/ 10665/68925/EIP_GPE_EQC_2003_1.pdf;sequence=1.

Previous Article
The theoretical and practical research and effect evaluation at home and abroad: a review of integrated care
Next Article
Application of adaptive randomization in clinical trials

Chinese Journal of Evidence-Based Medicine

Quality evaluation of esophageal cancer clinical guidelines and consensus

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content